Clinical trials: Respiratory Tract Infection Viral
Covid19, Paludism
Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID)
In this study, the investigators will explore the reasons for the apparently lower proportion of severe COVID-19 cases in many sub-Sahara African countries.
- Trial name
- Palu-COVID (NCT05012280)
- Where
- Democratic Republic of the Congo
- Volunteers
- 238 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT02381418
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott
COVID-19
Communities Fighting COVID Return to School
San Diego State University (SDSU), a designated Hispanic-serving institution, is partnering with Sweetwater Union High School District, an independent public school district serving 90% ethnic minority and a high proportion of…
- Trial name
- NCT05150860
- Testing
- At-home COVID-19 testing, Onsite COVID-19 testing
- Where
- United States
- Volunteers
- 852 people, healthy volunteers welcome
- Sponsor
- San Diego State University
COVID-19, Myocardial Injury
Myocardial Injury and Quality of Life After COVID-19
In this observational study follow-up and dynamic observation will be conducted on the participants recovered from pneumonia caused by COVID-19.
- Conditions
- COVID-19, Myocardial Injury, Myocarditis Post Infection
- Trial name
- NCT04794062
- Where
- Russia
- Volunteers
- 119 people
- Sponsor
- Voronezh Regional Clinical Consultative and Diagnostic Center
Neoplasms Malignant, Covid19
Thromboembolic Risk Screening in Patients With Cancer and COVID-19
Study Rational Since December 2019, outbreak of COVID-19 caused by a novel virus SARS-Cov-2 has spread rapidly around the world and became a pandemic issue.
- Conditions
- Neoplasms Malignant, Covid19, Thromboembolism
- Trial name
- NEOTHROCOVID (NCT04616846)
- Testing
- Peripheral venous ultrasound
- Where
- 6 sites in France, Monaco
- Volunteers
- 88 people
- Sponsor
- Centre Antoine Lacassagne
Influenza
Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
This randomized, double-blinded trial will assess humoral immune responses to adjuvanted, egg-based quadrivalent influenza vaccines compared to standard dose, egg-based quadrivalent influenza vaccines among healthcare personnel…
- Trial name
- EDUCATE (NCT06054269)
- Testing
- FLUAD Quadrivalent, FluQuadri
- Where
- 2 sites in Peru
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Covid19, Severe Acute Respiratory Syndrome
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
- Trial name
- COUGH-1 (NCT04839146)
- Testing
- ABNCoV2 Vaccine
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Coronavirus Disease-2019 (COVID-19) Prevention
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune response of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule or as a 2-dose schedule (56-day interval) in adolescents.
- Trial name
- HORIZON 2 (NCT05007080)
- Testing
- Ad26.COV2.S
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
COVID-19
COVID-19 PrEP HCW HCQ Study
Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04354870
- Testing
- Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- NYU Langone Health
Covid19, SARS-CoV-2 Infection
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
A Trial of GC4419 in Patients with Critical Illness due to COVID-19
- Trial name
- NCT04555096
- Testing
- GC4419
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Galera Therapeutics, Inc.
Influenza
Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza causes epidemics of respiratory infection in young children each winter. Young children, particularly those under 6 months of age are most vulnerable to suffering from complications secondary to influenza infection.
- Trial name
- Piiitch (NCT00570037)
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 2 sites in United States
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- Duke University
Quality of Life, Injection Site Reaction
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or…
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Trial name
- NCT05028361
- Testing
- mRNA COVID-19, IIV4
- Where
- 3 sites in United States
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19
Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19
The objective of this study is to determine the safety, feasibility and efficacy of a bidirectional oxygenation Positive End Expiratory Pressure (PEEP) mouthpiece in coronavirus disease 2019 (COVID-19) patients requiring…
- Trial name
- GO2 PEEP (NCT04331366)
- Testing
- GO2 PEEP MOUTHPIECE
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Influenza (Healthy Volunteers)
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea
To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (>=) 50 years of age participants by…
- Trial name
- NCT05144945
- Testing
- Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4)
- Where
- 3 sites in South Korea
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cognitive Dysfunction, Covid19
Improving Cognitive Health in COVID-19 Survivors
The primary objective of this study is to investigate the efficacy of AKL-T01, a remotely-delivered digital cognitive intervention, relative to a waitlist control in improving cognitive functioning in COVID-19 survivors.
- Trial name
- NCT04843930
- Testing
- AKL-T01
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Weill Medical College of Cornell University
COVID-19
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days.
- Trial name
- NCT04313023
- Testing
- PUL-042 Inhalation Solution
- Where
- 15 sites in United States
- Volunteers
- 217 people
- Sponsor
- Pulmotect, Inc.
Covid19
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization.
- Trial name
- COPPS (NCT04662073)
- Testing
- Camostat
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
COVID-19
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients.
- Trial name
- NCT05822583
- Testing
- abatacept infusion
- Where
- 127 sites in United States, Australia and 17 more
- Volunteers
- 285 people
- Sponsor
- University of Minnesota
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.